Ying Liu, Jacquelyn Bainbridge, Stefan Sillau, Sarah Rajkovic, Michelle Adkins, Christopher H Domen, John A Thompson, Tristan Seawalt, Jost Klawitter, Cristina Sempio, Grace Chin, Lisa Forman, Michelle Fullard, Trevor Hawkins, Lauren Seeberger, Heike Newman, David Vu, Maureen Anne Leehey
BACKGROUND: Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks. OBJECTIVE: The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) to provide preliminary data for a longer trial. METHODS: Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) who had negative cannabis testing took cannabis extract (National Institute of Drug Abuse) oral sesame oil solution for 2 weeks, increasing to final dose of 2...
March 15, 2024: Movement Disorders: Official Journal of the Movement Disorder Society